# Chemical Science

# EDGE ARTICLE

Check for updates

Cite this: Chem. Sci., 2018, 9, 2991

# Gold-catalyzed [4+3]- and [4+2]-annulations of 3-en-1-ynamides with isoxazoles *via* novel $6\pi$ -electrocyclizations of 3-azahepta trienyl cations<sup>†</sup>

New gold-catalyzed [4+3]-annulations of 3-en-1-ynamides with isoxazoles afford 4*H*-azepines efficiently; this process involves  $6\pi$  electrocyclizations of gold-stabilized 3-azaheptatrienyl cations. In the presence of Zn(OTf)<sub>2</sub>, the resulting 4*H*-azepines undergo skeletal rearrangement to furnish substituted pyridine

derivatives. We subsequently develop new catalytic [4+2]-annulations between the same 3-en-1-

ynamides and isoxazoles to deliver substituted pyridine products using Au(1)/Zn(11) catalysts. This work

reports the first success of the  $6\pi$  electrocyclizations of heptatrienyl cations that are unprecedented in

Sovan Sundar Giri and Rai-Shung Liu<sup>®</sup>\*

Received 15th January 2018 Accepted 18th February 2018


DOI: 10.1039/c8sc00232k

rsc.li/chemical-science

# Introduction

Electrocyclizations of acyclic conjugated  $\pi$ -motifs are powerful tools to access five-, six- and seven-membered carbocycles;<sup>1</sup> prominent examples include Nazarov cyclizations of pentadienyl cations<sup>2</sup> and  $6\pi$  electrocyclizations of trienes,<sup>3</sup> which have found widespread applications in organic synthesis.

literature reports.




Scheme 1 Electrocyclizations of conjugated  $\pi$ -motifs.

In the context of seven-carbon  $\pi$ -motifs, heptatrienyl anions I undergo facile  $8\pi$  electrocyclizations *via* rapid interconversions among various anion configurations (Scheme 1).<sup>4</sup> In contrast, heptatrienyl cations III<sup>5</sup> exclusively undergo Nazarov reactions because of the difficulties of forming all  $\sigma$ -*cis* configured cations V that have a high energy state.<sup>5b</sup> 1-Aza- and 1-oxaheptatrienyl cations<sup>6</sup> were also reported to follow Nazarov cyclizations. The realization of a  $6\pi$  electrocyclization of conjugated seven-membered cations is formidable but challenging. This work reveals the first success of such seven-membered cyclizations of gold-stabilized 3-azaheptatrienyl cations V' to form azacyclic products 3–4 *via* a new C–C bond formation.

YAL SOCIETY CHEMISTRY

View Article Online

View Journal | View Issue



The advent of gold catalysis has inspired new annulations between alkynes and poor nucleophiles.<sup>7</sup> N–O containing nucleophiles serve as useful building blocks to construct valuable azacyclic frameworks.<sup>7</sup> Ye and Hashmi reported interesting [3+2]-annulations of isoxazoles or benzisoxazoles with electron-

Department of Chemistry, National Tsing-Hua University, Hsinchu, Taiwan, Republic of China. E-mail: rsliu@mx.nthu.edu.tw

<sup>†</sup> Electronic supplementary information (ESI) available. CCDC 1589549, 1589562, 1589561, 1589558, 1589559 and 1589560. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c8sc00232k


rich ynamides, yielding substituted pyrrole derivatives through aza-Nazarov cyclizations of the key intermediate [eqn (1)].<sup>7,8</sup> These [3+2]-annulations were extensively expanded to other N–O heterocycles including benzisoxazoles, 1,2,4-oxadiazoles, 1,4,2-dioxazoles and 4,5-dihydro-1,2,4-oxadiazoles, yielding additional five-membered azacycles as depicted in [eqn (1)].<sup>9</sup> Here, we report two distinct [4+3]- and [4+2]-annulations between 3-en-1-ynamides and isoxazoles using varied catalysts. An Au(1) catalyst alone delivers 4*H*-azepines 3–4 through  $6\pi$  electrocyclizations of intermediates V' [eqn (2)] whereas a combined action of Au(1)/Zn( $\pi$ ) on the same reactants furnishes highly functionalized pyridines 5 [eqn (3)]. With our convenient synthesis, the synthetic utility of new 4*H*-azepines 3–4 is also reported.<sup>10</sup>

# **Results and discussion**

We examined the reactions of 3-methyl-3-en-1-ynamide **1a** with 3,5-dimethylisoxazole **2a** using various gold catalysts. Heating this mixture (1a/2a = 1 : 2 ratio) in hot DCE with 5 mol% LAuCl/AgNTf<sub>2</sub> [L =  $p(t\text{-Bu})_2(o\text{-biphenyl})$  and IPr] afforded a [4+3]-annulation product, 4*H*-azepine **3a**, in 64% and 75% yields respectively (Table 1, entries 1–2). Under these conditions, a low loading (1.2 equiv.) of 3,5-dimethylisoxazole **2a** gave **3a** in a decreased yield, *ca.* 62% (entry 3). With a 10 mol% catalyst, IPrAuCl/AgNTf<sub>2</sub> gave a clean reaction, yielding desired **3a** up to 91% (entry 4). We tested other phosphine ligands such as PPh<sub>3</sub> and P(OPh)<sub>3</sub>, yielding desired **3a** in satisfactory yields (78–81%, entries 5–6). Other counter anions such as OTf<sup>-</sup> and SbF<sub>6</sub><sup>-</sup> were also effective in producing **3a** in 85–88% yields (entries 7–8). AgNTf<sub>2</sub> alone was not active at all (entry 9).

| Table 1 [4+3]-Annulations over various gold catalysts   |   |  |                                       |                |   |  |  |  |
|---|---|--|---------------------------------------|----------------|---|--|--|--|
| $\begin{array}{c} & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & &$ |   |  |                                       |                |   |  |  |  |
|   |   |  |                                       |                | Yield <sup>b</sup> [%]                        |  |  |  |
| Entry   | Catalyst [mol%]   | x                                      | Time                                  |                |   |  |  |  |
|   |   |  | [h]                                   | 1a             | 3a  | 1a-H'/1a-H"  |  |  |
| 1 <sup>c</sup>  | LAuCl/AgNTf <sub>2</sub> [5]  | 2                                      | 3                                     | 1a<br>20       | 3a<br>64                                      | 1a-H'/1a-H"  |  |  |
| -   |   |  |                                       |                |   | _  |  |  |
| $2^d$   | LAuCl/AgNTf <sub>2</sub> [5]  | 2                                      | 3                                     | 20             | 64  | 7 [2.5 : 1]  |  |  |
| 2 <sup>d</sup><br>3   | LAuCl/AgNTf <sub>2</sub> [5]<br>IPrAuCl/AgNTf <sub>2</sub> [5]  | 2<br>2                                 | 3<br>7                                | 20<br>12       | 64<br>75                                      | 7 [2.5 : 1]  |  |  |
| 2 <sup>d</sup><br>3<br><b>4</b>   | LAuCl/AgNTf <sub>2</sub> [5]<br>IPrAuCl/AgNTf <sub>2</sub> [5]<br>IPrAuCl/AgNTf <sub>2</sub> [5]  | 2<br>2<br>1.2                          | 3<br>7<br>7                           | 20<br>12<br>23 | 64<br>75<br>62                                |  |  |  |
| 2 <sup>d</sup><br>3<br><b>4</b><br>5  | LAuCl/AgNTf <sub>2</sub> [5]<br>IPrAuCl/AgNTf <sub>2</sub> [5]<br>IPrAuCl/AgNTf <sub>2</sub> [5]<br><b>IPrAuCl/AgNTf<sub>2</sub> [10]</b><br>PPh <sub>3</sub> AuCl/AgNTf <sub>2</sub> [10]<br>[PhO] <sub>3</sub> PAuCl/AgNTf <sub>2</sub> [10]                                    | 2<br>2<br>1.2<br>2                     | 3<br>7<br>7<br>3                      | 20<br>12<br>23 | 64<br>75<br>62<br><b>91</b>                   | <br>7 [2.5 : 1]<br>5 [1 : 1]<br><b>Trace</b><br>5 [1.25 : 1]<br>13 [1.1 : 1] |  |  |
| 2 <sup>d</sup><br>3<br>4<br>5<br>6<br>7   | LAuCl/AgNTf <sub>2</sub> [5]<br>IPrAuCl/AgNTf <sub>2</sub> [5]<br>IPrAuCl/AgNTf <sub>2</sub> [5]<br><b>IPrAuCl/AgNTf<sub>2</sub> [10]</b><br>PPh <sub>3</sub> AuCl/AgNTf <sub>2</sub> [10]<br>[PhO] <sub>3</sub> PAuCl/AgNTf <sub>2</sub> [10]<br>IPrAuCl/AgSbF <sub>6</sub> [10] | 2<br>2<br>1.2<br>2<br>2<br>2<br>2<br>2 | 3<br>7<br>7<br>3<br>3.5<br>3.5<br>2.5 | 20<br>12<br>23 | 64<br>75<br>62<br><b>91</b><br>81<br>78<br>85 |  |  |  |
| 1 <sup>c</sup><br>2 <sup>d</sup><br>3<br>4<br>5<br>6<br>7<br>8<br>9   | LAuCl/AgNTf <sub>2</sub> [5]<br>IPrAuCl/AgNTf <sub>2</sub> [5]<br>IPrAuCl/AgNTf <sub>2</sub> [5]<br><b>IPrAuCl/AgNTf<sub>2</sub> [10]</b><br>PPh <sub>3</sub> AuCl/AgNTf <sub>2</sub> [10]<br>[PhO] <sub>3</sub> PAuCl/AgNTf <sub>2</sub> [10]                                    | 2<br>2<br>1.2<br>2<br>2<br>2           | 3<br>7<br>7<br>3<br>3.5<br>3.5        | 20<br>12<br>23 | 64<br>75<br>62<br><b>91</b><br>81<br>78       | <br>7 [2.5 : 1]<br>5 [1 : 1]<br><b>Trace</b><br>5 [1.25 : 1]<br>13 [1.1 : 1] |  |  |

<sup>*a*</sup> [1a] = 0.15 M. <sup>*b*</sup> Product yields are reported after separation from a silica column. <sup>*c*</sup> L =  $p(t-Bu)_2(o-biphenyl)$ . <sup>*d*</sup> IPr = 1,3-bis(diisopropylphenyl)-imidazol-2-yildene. Ms = methanesulfonyl, DCE = 1,2-dichloroethane, and Tf = trifluoromethanesulfonyl.



(11) (**3I**, 2.5 h, 48%, **x-ray**) (**6I**, 43%, *E/Z*= 3.3:1) (12) (**3m**, 14 h, 16%) (**6m**, 73%, **x-ray**)

 $a^{a}$  [1] = 0.15 M.  $b^{b}$  Product yields are reported after separation from a silica column. EWG = electron withdrawing group.


 Table 3
 [4+3]-Annulations with various isoxazoles

| الله<br>۱b <sup>a</sup> | $\frac{N}{T_{s}} + \frac{R^{1}}{N_{O}} + \frac{R^{2}}{R^{2}}$ | IPrAu<br>DCI | mol %<br>Cl/AgNTf <sub>2</sub><br>E, 70 °C<br>time R <sup>2</sup>      | $ \begin{array}{c}                                     $ | O<br>N<br>Ts             |
|-------------------------|---|--------------|--|--|--------------------------|
| Entry                   | $(R^1, R^2)$  | 2            | Time [h]   | Yield [%]  | 4                        |
| (1)                     | Н, Н  | 2b           | 4  | 84<br>8  | <b>4a</b> (X-ray)<br>7a' |
| (2)                     | H, Me   | 2d           | 3  | o<br>75  | 7a<br>4b                 |
| (3)                     | Me, H   | 2u<br>2c     | 3  | 87   | 4c                       |
| (4)                     | Et, Et  | 2e           | 6  | 85   | 4d                       |
| (5)                     | <i>n</i> -Bu, <i>n</i> -Bu                                    | 2f           | 7  | 81   | 4e                       |
| (6)                     | Me, <i>n</i> -Bu  | 2g           | 3  | 82   | 4 <b>f</b>               |
| (7)                     | <i>n</i> -Bu, <i>c</i> -Pr                                    | 2h           | 2  | 77   | 4g                       |
| (8)                     | Ph, <i>n</i> -Bu  | 2i           | 4  | 69   | 4h                       |
| (9)                     | Ph, Ph  | 2j           | 6.5  | 61   | 4i                       |
|                         |   |              |  | 30   | 5i (X-ray)               |
| (10)                    | Me, Ph  | 2k           | 4  | 71   | 4j                       |
|                         | Ph<br>O<br>R <sup>1</sup> N                                   |              | R <sup>1</sup> = Ph ( <b>5i</b> )<br>R <sup>1</sup> = Me ( <b>5j</b> ) | 15   | 5j                       |

 $^{a}\left[\mathbf{1b}\right]=0.15$  M.  $^{b}$  Product yields are reported after separation from a silica column.

Suitable substituents of 3-en-1-ynamides **1** are crucial to achieve  $6\pi$  cyclizations of 3-azaheptatrienyl cations **V**' [eqn (2)]. We tested the reactions on 3-en-1-ynes **1b–1m** bearing a C(3)-substituent to circumvent aza-Nazarov cyclizations as reported in Ye's work.<sup>7</sup> Herein, only entries 9 and 10 showed the presence of 3-azanorcaradienes **3'**. We examined these [4+3]-annulations on 3-methyl-3-en-1-ynamides **1b–1e** bearing various sulfon-amides NTsR<sup>4</sup> (R<sup>4</sup> = Me, cyclopropyl, benzyl and N(*n*-C<sub>4</sub>H<sub>9</sub>) ( $-SO_2Bu$ )), affording the desired 4*H*-azepines **3b–3e** in high yields (84–90%, Table 2, entries 1–4). Nevertheless, this new annulation becomes less efficient for 3-en-1-ynamide **1f** bearing an oxazolidin-2-one to yield product **3f** in 64% yield (entry 5).

We altered the C(3)-substituents as in substrates **1g–1i**; their resulting products **3g–3h** ( $\mathbb{R}^1$  = isopropyl and cyclopropyl) were obtained in 74–79%, and **3i** ( $\mathbb{R}^1$  = Ph) with only 58% yield (entries 6–8). Notably, when a long *n*-butyl group was present as in species **1j** and **1k**, their corresponding reactions afforded compounds **3j/3j'** = 5/1 and **3k/3k'** = **11.1 : 1**, respectively, in 55% and 68% yields (entries 9–10). For *E*-configured trisubstituted 3-en-1-yne **1l** ( $\mathbb{R}^1$  = Me,  $\mathbb{R}^2$  = Ph and  $\mathbb{R}^3$  = H), 4*H*-azepine **3l** 



Scheme 2 New functionalization of 4H-azepines.


and pyrrole **6l** were obtained in equal proportions (entry 11). When a cyclohexenyl group was present for alkene as in species **1m**, pyrrole product **6m** was dominant over azepine **3m** (entry 12). Accordingly, preferable 3-en-1-ynes comprise a small  $\mathbb{R}^2$  or  $\mathbb{R}^3$  substituent whereas  $\mathbb{R}^1$  must be substituted. Herein, the structures of 4*H*-azepines **3b** and **3l**, and pyrrole species **6m** were confirmed with X-ray diffraction.<sup>11</sup>

Isoxazoles of a wide scope are compatible with these [4+3]annulations, as depicted in Table 3. The reaction of unsubstituted isoxazole 2b with model 3-en-1-ynamide 1b afforded the desired 4*H*-azepine 4a in 84% yield, together with pyrrole 7a' in only 8% yield (entry 1). Mono-substituted 3-methyl or 5-methyl isoxazoles 2c and 2d are also suitable for these annulations to afford compounds 4b and 4c in 75% and 87% yields, respectively (entries 2–3). We prepared additional 3,5-disubstituted isoxazoles 2e–2i with  $R^1$  = alkyl and phenyl, and  $R^2$  = alkyl; their annulations proceed smoothly to produce desired 4d–4h in 69– 85% yields (entries 4–8). For di-substituted isoxazoles 2j and 2k bearing  $R^2$  = Ph, 4*H*-azepines 4i and 4j were obtained in 61% and 71% yields respectively, together with their rearrangement products 5i and 5j in 15–30% yields (entries 9–10). Compounds 4a and 5i were characterized by X-ray diffraction.<sup>11</sup>

Our convenient synthesis of 4*H*-azepines provides new synthetic utilities; several new functionalizations are depicted in Scheme 2. NaBH<sub>4</sub>-reduction of species **3b** delivered an alcohol derivative **7a** in 84% yield. Selective hydrogenation of the same species afforded 2-aza-1,3-dien-5-one **7b** in 71% yield. A final treatment of 4*H*-azepine **3b** with NBS in acetone afforded compound **7c**, of which the molecular structure was determined by <sup>1</sup>H NOE spectra.


The Lewis-catalyzed rearrangement of 4*H*-azepines **3–4** to substituted pyridines **5** [eqn (3)] is unprecedented in 4*H*-azepine chemistry.<sup>10</sup> We undertook such novel [4+2]-annulations

| Table 4 | [4+2]-Annulations | between 3-en-1- | ynamides and isoxazoles |
|---------|-------------------|-----------------|-------------------------|
|         |                   |                 |                         |



| Entry | $(R^1, R^2, EWG)$    | 1  | $(R^3, R^4)$               | 2          | Time [h] | Yield [%]   | 5                 |
|-------|----------------------|----|----------------------------|------------|----------|-------------|-------------------|
| (1)   | Me, Me, Ts           | 1b | Me, Me                     | 2a         | 19       | $73 (35)^c$ | <b>5a</b> (X-ray) |
| (2)   | <i>n</i> -Bu, Me, Ts | 1k | Me, Me                     | 2a         | 33       | 64          | 5b                |
| (3)   | <i>c</i> -Pr, Me, Ts | 1h | Me, Me                     | 2a         | 20       | 56          | 5c                |
| (4)   | <i>i</i> -Pr, Me, Ts | 1g | Me, Me                     | 2a         | 15       | 51          | 5 <b>d</b>        |
| (5)   | Me, <i>n</i> -Bu, Ms | 1a | Me, Me                     | 2a         | 28       | 63          | 5e                |
| (6)   | Me, Me, Ts           | 1b | <i>n</i> -Bu, <i>n</i> -Bu | 2 <b>f</b> | 19       | 78          | 5f                |
| (7)   | Me, Me, Ts           | 1b | Et, Et                     | 2e         | 16       | 69          | 5g                |
| (8)   | Me, Me, Ts           | 1b | nBu, c-Pr                  | 2h         | 20       | 75          | 5 <b>h</b>        |
| (9)   | Me, Me, Ts           | 1b | Ph, Ph                     | 2j         | 24       | 80          | 5i (X-ray)        |
| (10)  | Me, Me, Ts           | 1b | Me, Ph                     | 2k         | 30       | 75          | 5j                |

a [1] = 0.15 M. b Product yields are reported after separation from a silica column. c The value in parentheses is reported using a mixture of IPrAuCl/AgNTf<sub>2</sub> (10 mol%) and Zn(OTf)<sub>2</sub> (20 mol%) in hot DCE (70 °C, 48 h); **3b** was also isolated in 28% yield.



Scheme 3 A plausible reaction mechanism.

between 3-en-1-ynamides 1 and isoxazoles 2 using Au(I)/Zn(II) in a relay series, as depicted in Table 4. In the reactions of various 3-substituted 3-en-1-ynamides 1 ( $\mathbb{R}^1$  = methyl, *n*-butyl, cyclopropyl and isopropyl) with 3,5-dimethylisoxazole 2a, substituted pyridines 5a-5d were obtained in satisfactory yields (51-73%, entries 1-4). In entry 1, if the reaction was performed with combined Au(I)/Zn(II) catalysts in a non-relay operation, compounds 5a and 3b were isolated in 35% and 28% yields respectively. For 3-en-1-ynamide 1a bearing a NMs(n-butyl), the corresponding product 5e was obtained in 63% yield (entry 5). We tested the reactions on 3,5-disubstituted isoxazoles 2e-2f & 2h bearing all alkyl substituents, producing desired 5f-5h in good yields (69-78%, entries 6-8). For such disubstituted isoxazoles bearing  $R^4 = Ph$ , the reactions afforded the desired pyridine derivatives 5i and 5j in 75-80% yields (entries 9-10). The molecular structures of compounds 5a and 5i were characterized by X-ray diffraction.11

Scheme 3 rationalizes the crucial roles of substituents of 3en-1-ynamides in the chemoselectivity that relies on two conformational structures D versus D'. The N-attack of isoxazole at gold- $\pi$ -ynamide A is expected to form a gold-carbene D', which can be visualized as a gold-stabilized cycloheptatrienyl cation. Conformation **D** is favorable with R = H, which prefers aza-Nazarov reactions.<sup>12</sup> When a C(3)-substituent is present (R = alkyl and aryl), all  $\sigma$ -*cis* configured species **D**' are the preferable geometry to induce novel  $6\pi$  electrocyclizations. This ring closure is expected to proceed through an attack of enamide at the alkenylgold moiety that is also visualized as a goldstabilized cation. Additional C(4)-substituents render the formation of cations D' difficult, thus yielding pyrrole 6 as byproducts. A loss of an acidic proton from seven-membered cations E is expected to yield azepines 3-4. 4H-Azepines 3-4 bear an enone conjugated with a triene; this extensive conjugation is very stable to impede a  $6\pi$  electrocyclization of their triene moieties unless a Lewis acid is present. Zn(OTf)<sub>2</sub> likely coordinates with the carbonyl of 4H-azepine 3 to generate a 2azapentadienyl cation F bearing a zinc enolate, further enabling an intramolecular cyclization to generate species G. A 1,2-acyl shift<sup>14</sup> of species G delivers the observed product 5.<sup>13</sup>

#### Conclusions

In summary, this work describes new gold-catalyzed [4+3] annulations<sup>15</sup> of 3-substituted 3-en-1-ynamides with isoxazoles to form 4*H*-azepines. A relay catalysis is also developed with Au(1)/Zn(II) catalysts to achieve [4+2] annulations from the same reactants. The mechanisms of gold-catalyzed [4+3] annulations involve unprecedented  $6\pi$  electrocyclizations of 3-azacycloheptatrienyl cations to form 4*H*-azepines **3**–**4** efficiently. Control experiments confirm that 4*H*-azepines **3**–**4** are catalyzed by Zn(OTf)<sub>2</sub> to undergo new rearrangement reactions to form substituted pyridine derivatives.

## Conflicts of interest

The authors declare no conflict of interest.

## Acknowledgements

The authors thank the Ministry of Science and Technology and the Ministry of Education, Taiwan, for supporting this work.

## Notes and references


- (a) S. Sankararaman, in Pericyclic Reactions-A Textbook. Reactions, Applications and Theory, Wiley-VCH, New York, 2005, ch. 6, pp. 393-398; (b) C. M. Beaudry, J. P. Malerich and D. Trauner, Chem. Rev., 2005, 105, 4757; (c) P. V. R. Schleyer, J. I. Wu, F. P. Cossio and I. Fernandez, Chem. Soc. Rev., 2014, 43, 4909; (d) M. Bian, L. Li and H. Ding, Synthesis, 2017, 49, 4383; (e) E. C. Taylor and I. J. Turchi, Chem. Rev., 1979, 79, 181; (f) F. D. Proft, P. K. Chattaraj, P. W. Ayers, M. T. Sucarrat, M. Elango, V. Subramanian, S. Giri and P. Geerlings, J. Chem. Theory Comput., 2008, 4, 595; (g) N. Jana and G. Driver, Org. Biomol. Chem., 2015, 13, 9720.
- 2 (a) W. T. Spencer III, T. Vaidya and A. J. Frontier, *Eur. J. Org. Chem.*, 2013, 3621; (b) R. L. Davis and D. L. Tantillo, *Curr. Org. Chem.*, 2010, 14, 1561; (c) T. N. Grant, C. J. Rieder and

F. G. West, *Chem. Commun.*, 2009, 5676; (*d*) M. J. Riveira, L. A. Marsili and M. P. Mischne, *Org. Biomol. Chem.*, 2017, 15, 9255; (*e*) N. Shimada, C. Stewart and M. A. Tius, *Tetrahedron*, 2011, **67**, 5851.

- 3 (a) V. A. Guner, K. N. Houk and I. W. Davis, J. Org. Chem., **69**, 8024; (b) R. V. Essen, D. Frank, 2004. H. W. Sunnemann, D. Vidovic, J. Magull and A. D. Meijere, Chem.-Eur. J., 2005, 11, 6583; (c) N. A. Magomedov, P. L. Ruggiero and Y. Tang, J. Am. Chem. Soc., 2004, 126, 1624; (d) E. N. Marvell, G. Caple, B. Schatz and W. Pippin, Tetrahedron, 1973, 29, 3781; (e) J. R. Otero, J. Org. Chem., 1999, 64, 6842; (f) P. E. Tessier, N. Nguyen, M. D. Clay and A. G. Fallis, Org. Lett., 2005, 7, 767; (g) C. L. Benson and F. G. West, Org. Lett., 2007, 9, 2545; (h) G. A. Barcan, A. Patel, K. N. Houk and O. Kwon, Org. Lett., 2012, 14, 5388. 4 (a) R. B. Bates, W. H. Delnes, D. A. McCombs and D. E. Potter, J. Am. Chem. Soc., 1969, 91, 4608; (b) K. Marx and W. Eberbach, Chem.-Eur. J., 2000, 6, 2063; (c) M. Reisser and G. Mass, J. Org. Chem., 2004, 69, 4913; (d) T. Hübner, Dissertation, University of Freiberg, 1987; (e) A. Arany, D. Bendell, P. W. Groudwater, I. Garnett and M. Nyerges, J. Chem. Soc., Perkin Trans. 1, 1999, 2605.
- 5 (*a*) N. C. Deno, C. U. Pittman and J. O. Turner, *J. Am. Chem. Soc.*, 1965, **87**, 2153; (*b*) O. N. Faza, C. S. López, R. Alvarez and A. R. de Lera, *Chem.-Eur. J.*, 2009, **15**, 1944.
- 6 D. Alickmann, R. Fröhlich, A. H. Maulitz and E. U. Wurthwein, *Eur. J. Org. Chem.*, 2002, 1523.
- 7 (a) A. H. Zhou, Q. He, C. Shu, Y. F. Yu, S. Liu, T. Zhao, W. Zhang, X. Lu and L. W. Ye, *Chem. Sci.*, 2015, 6, 1265; (b) X. Y. Xiao, A. H. Zhou, C. Shu, F. Pan, T. Li and L. W. Ye, *Chem.-Asian J.*, 2015, 10, 1854; (c) W. B. Shen, X. Y. Xiao, Q. Sun, B. Zhou, X. Q. Zhu, J. Z. Yan, X. Lu and L. W. Ye, *Angew. Chem., Int. Ed.*, 2017, 56, 605; (d) L. Li, T. D. Tan, Y. Q. Zhang, X. Liu and L. W. Ye, *Org. Biomol. Chem.*, 2017, 15, 8483.
- 8 (a) H. Jin, L. Huang, J. Xie, M. Rudolph, F. Rominger and A. S. K. Hashmi, *Angew. Chem., Int. Ed.*, 2016, 55, 794; (b) H. Jin, B. Tian, X. Song, J. Xie, M. Rudolph, F. Rominger and A. S. K. Hashmi, *Angew. Chem., Int. Ed.*, 2016, 55, 12688.
- 9 (a) Z. Zeng, H. Jin, J. Xie, B. Tian, M. Rudolph, F. Rominger and A. S. K. Hashmi, Org. Lett., 2017, 19, 1020; (b) M. Chen, N. Sun, H. Chen and Y. Liu, Chem. Commun., 2016, 52, 6324; (c) W. Xu, G. Wang, N. Sun and Y. Liu, Org. Lett., 2017, 19, 3307.
- 10 For synthesis of *nH*-azepines (n = 2 or 4), see selected examples: (a) U. Gockel, U. Hartmannsgruber, A. Steigel and J. Sauer, *Tetrahedron Lett.*, 1980, **21**, 599; (b)

I. R. Dunkin, A. E. Ayeb and M. A. Lynch, *J. Chem. Soc., Chem. Commun.*, 1994, 1695; (*c*) K. Satake, R. Okuda, M. Hashimoto, Y. Fujiwara, H. Okamoto, M. Kimura and S. Morosawa, *J. Chem. Soc. Perkin Trans 1*, 1994, 1753; (*d*) Y. Luo and J. Wu, *Chem. Commun.*, 2011, 47, 11137.

- 11 Crystallographic data of compounds **3b**, **3l**, **4a**, **5a**, **5i**, and **6m** were deposited in Cambridge Crystallographic Data Center: **3b**: CCDC 1589549, **3l**: CCDC 1589562, **4a**: CCDC 1589561, **5a**: CCDC 1589558, **5i**: CCDC 1589559 and **6m** CCDC 1589560.<sup>†</sup>
- 12 For the aza-Nazarov cyclizations, see: (a) D. A. Klumpp,
  Y. Zhang, M. J. O'Connor, P. M. Esteves and L. S. de Almeida, Org. Lett., 2007, 9, 3085; (b) Z. X. Ma, S. He,
  W. Song and R. P. Hsung, Org. Lett., 2012, 14, 5736; (c)
  R. L. Sahani and R. S. Liu, Angew. Chem., Int. Ed., 2017, 56, 12736; (d) S. K. Pawar, R. L. Sahani and R. S. Liu, Chem.-Eur. J., 2015, 21, 10843; (e) C. Shu, Y. H. Wang, C. H. Shen,
  P. P. Ruan, X. Lu and L. W. Ye, Org. Lett., 2016, 18, 3254.
- 13 As suggested by one reviewer, an alternative mechanism is also possible for the Zn(n)-catalyzed rearrangement; this process involves an isomerization of initial species 3 to an unconjugated iminoyl ketone **H**, followed by a  $6\pi$ cyclization to generate species **I**. A subsequent Zn(n)catalyzed aromatization of species **I** is expected to yield the final product 5. In this process, species **H** is relatively higher than 3 in energy, but its feasibility is not excluded.



- 14 (a) S. M. Wang and L. Zhang, Org. Lett., 2006, 8, 4585; (b)
  G. Li, G. Zhang and L. Zhang, J. Am. Chem. Soc., 2008, 130, 3704; (c) S. B. Wagh and R. S. Liu, Chem. Commun., 2015, 51, 15462; (d) R. Chaudhuri, A. Das, H. Y. Liao and R. S. Liu, Chem. Commun., 2010, 46, 4601.
- 15 For reviews of gold-catalyzed cycloaddition or annulation reactions of alkynes, see(a) D. J. Gorin, B. D. Sherry and F. D. Toste, *Chem. Rev.*, 2008, **108**, 3351; (b)
  A. S. K. Hashmi, *Chem. Rev.*, 2007, **107**, 3180; (c) F. López and J. L. Mascareñas, *Beilstein J. Org. Chem.*, 2011, 7, 1075; (d) C. Aubert, L. Fensterbank, P. Garcia, M. Malacria and A. Simonneau, *Chem. Rev.*, 2011, **111**, 1954; (e)
  D. Garayalde and C. Nevado, *ACS Catal.*, 2012, **2**, 1462; (f)
  M. E. Muratore, A. Homes, C. Obradors and A. M. Echavarren, *Chem.-Asian J.*, 2014, **9**, 3066.